Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Entsufon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.53 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.53 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.53 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.53 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.53 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | APAF1 | O14727 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9397617 | 1.00 | CYP3A4 (0.56) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL30743063 | 0.88 | CYP3A4 (0.55) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL6859207 | 0.86 | CYP3A4 (0.60) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| Entsufon SCHEMBL29382695 | 0.86 | CYP3A4 (0.60) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL4542317 | 0.85 | CYP3A4 (0.58) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL8506131 | 0.85 | CYP3A4 (0.58) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL8506128 | 0.85 | S1PR1 (0.42) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL15737711 | 0.83 | CYP3A4 (0.59) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| Potassium Ion SCHEMBL4542316 | 0.82 | S1PR1 (0.42) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A | |
| SCHEMBL13932431 | 0.81 | CYP3A4 (0.64) | CYP3A4SMN1; SMN2HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| US-20250312364-A1 | METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2025-10-09 | — | — | US | disclosed |
| US-20240307420-A1 | IMPROVED METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2024-09-19 | — | — | US | disclosed |
| US-11931452-B2 | Topical compositions containing rofecoxib and methods of making and using the same | JF PHARMA TECH LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4308128-A2 | IMPROVED METHODS FOR THE USE OF PSYCHEDELICS | Tryp Therapeutics Inc. (CA) | 2024-01-24 | — | — | EP | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | disclosed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-20010008877-A1 | Comprising acid solution having pH of 1 to 4 or basic solution having pH of 10 to 14, dispersible abrasive agent, surfactant, organic solvent, water | MAN ROLAND DRUCKMASCHINEN AG | 2001-07-19 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-1111036-A2 | Cleaning composition and use thereof | MAN Roland Druckmaschinen AG (DE) | 2001-06-27 | — | — | EP | disclosed |
| EP-0606219-A1 | WOUND CLEANSER | CARRINGTON LABORATORIES, INC. (US) | 1994-07-20 | — | — | EP | disclosed |
| US-5284833-A | Aqueous solution or dry concentrate of a surfactant, an osmotic adjuster and a buffer; nontoxic; biocompatability | CARRINGTON LABORATORIES, INC. (US) | 1994-02-08 | — | — | US | disclosed |
| WO-1993000100-A2 | WOUND CLEANSER | CARRINGTON LABORATORIES, INC. (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | NR3C1 711/4885ADORA3 3829/4885PTGS1 210/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | NR3C1 948/4885ADORA3 3924/4885PTGS1 2563/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | NR3C1 717/4885ADORA3 4043/4885PTGS1 2509/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | NR3C1 1292/4885ADORA3 4522/4885PTGS1 2437/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | NR3C1 630/4885ADORA3 3879/4885PTGS1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.